{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:28:11Z","timestamp":1793377691784,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The goal of this guideline\/procedure standard is to assist nuclear medicine physicians, other nuclear medicine professionals, oncologists or other medical specialists for recommended use of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT in oncological patients undergoing immunotherapy, with special focus on response assessment in solid tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a cooperative effort between the EANM, the SNMMI and the ANZSNM, clinical indications, recommended imaging procedures and reporting standards have been agreed upon and summarized in this joint guideline\/procedure standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The field of immuno-oncology is rapidly evolving, and this guideline\/procedure standard should not be seen as definitive, but rather as a guidance document standardizing the use and interpretation of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT during immunotherapy. Local variations to this guideline should be taken into consideration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Preamble<\/jats:title>\n                    <jats:p>The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association founded in 1985 to facilitate worldwide communication among individuals pursuing clinical and academic excellence in nuclear medicine. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote science, technology and practical application of nuclear medicine. The Australian and New Zealand Society of Nuclear Medicine (ANZSNM), founded in 1969, represents the major professional society fostering the technical and professional development of nuclear medicine practice across Australia and New Zealand. It promotes excellence in the nuclear medicine profession through education, research and a commitment to the highest professional standards. EANM, SNMMI and ANZSNM members are physicians, technologists, physicists and scientists specialized in the research and clinical practice of nuclear medicine. All three societies will periodically put forth new standards\/guidelines for nuclear medicine practice to help advance the science of nuclear medicine and improve service to patients. Existing standards\/guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each standard\/guideline, representing a policy statement by the EANM\/SNMMI\/ANZSNM, has undergone a thorough consensus process, entailing extensive review. These societies recognize that the safe and effective use of diagnostic nuclear medicine imaging requires particular training and skills, as described in each document. These standards\/guidelines are educational tools designed to assist practitioners in providing appropriate and effective nuclear medicine care for patients. These guidelines are consensus documents based on current knowledge. They are not intended to be inflexible rules or requirements of practice, nor should they be used to establish a legal standard of care. For these reasons and those set forth below, the EANM, SNMMI and ANZSNM caution against the use of these standards\/guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals considering the unique circumstances of each case. Thus, there is no implication that an action differing from what is laid out in the guidelines\/procedure standards, standing alone, is below standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the standards\/guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines\/procedure standards. The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible for general guidelines to consistently allow for an accurate diagnosis to be reached or a particular treatment response to be predicted. Therefore, it should be recognized that adherence to these standards\/ guidelines will not ensure a successful outcome. All that should be expected is that practitioners follow a reasonable course of action, based on their level of training, current knowledge, clinical practice guidelines, available resources and the needs\/context of the patient being treated. The sole purpose of these guidelines is to assist practitioners in achieving this objective. The present guideline\/procedure standard was developed collaboratively by the EANM, the SNMMI and the ANZSNM, with the support of international experts in the field. They summarize also the views of the Oncology and Theranostics and the Inflammation and Infection Committees of the EANM, as well as the procedure standards committee of the SNMMI, and reflect recommendations for which the EANM and SNMMI cannot be held responsible. The recommendations should be taken into the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-05780-2","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:02:52Z","timestamp":1649034172000},"page":"2323-2341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"E.","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"Seban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gheysens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Aide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"5780_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"13","key":"5780_CR2","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s00259-017-3802-5","volume":"44","author":"S Rossi","year":"2017","unstructured":"Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017;44(13):2310\u201325. https:\/\/doi.org\/10.1007\/s00259-017-3802-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"key":"5780_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","journal-title":"N Engl J Med"},{"key":"5780_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"5780_CR6","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/s1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374\u201385. https:\/\/doi.org\/10.1016\/s1470-2045(16)30364-3.","journal-title":"Lancet Oncol"},{"key":"5780_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98\u2013106. https:\/\/doi.org\/10.1097\/COC.0000000000000239.","journal-title":"Am J Clin Oncol"},{"key":"5780_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"key":"5780_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamaoncol.2018.4604","volume":"5","author":"S George","year":"2019","unstructured":"George S, Rini BI, Hammers HJ. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review. JAMA Oncol. 2019;5:411\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4604.","journal-title":"JAMA Oncol"},{"key":"5780_CR10","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","volume":"78","author":"RA Stewart","year":"2018","unstructured":"Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78:6717\u201325. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2652.","journal-title":"Cancer Res"},{"key":"5780_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"5780_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"5780_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377:1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"key":"5780_CR14","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1245\/s10434-018-6379-8","volume":"25","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. Ann Surg Oncol. 2018;25:1814\u201327. https:\/\/doi.org\/10.1245\/s10434-018-6379-8.","journal-title":"Ann Surg Oncol"},{"key":"5780_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(21)00065-6.","journal-title":"Lancet Oncol"},{"key":"5780_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/bjd.16347","volume":"178","author":"L Haas","year":"2018","unstructured":"Haas L, Wiesner T, Obenauf AC. A new era of proactive melanoma therapy: hit hard, hit early. Br J Dermatol. 2018;178:817\u201320. https:\/\/doi.org\/10.1111\/bjd.16347.","journal-title":"Br J Dermatol"},{"key":"5780_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"key":"5780_CR18","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624.","journal-title":"Clin Cancer Res"},{"key":"5780_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"5780_CR20","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.Ccr-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0895.","journal-title":"Clin Cancer Res"},{"key":"5780_CR21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"5780_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36:850\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.75.1644.","journal-title":"J Clin Oncol"},{"key":"5780_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809.","journal-title":"Science"},{"key":"5780_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421\u20138. https:\/\/doi.org\/10.2967\/jnumed.116.188839.","journal-title":"J Nucl Med"},{"key":"5780_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386\u201396. https:\/\/doi.org\/10.1007\/s00259-014-2944-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376\u201383. https:\/\/doi.org\/10.1007\/s00259-017-3870-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR27","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u201396. https:\/\/doi.org\/10.1182\/blood-2016-05-718528.","journal-title":"Blood"},{"key":"5780_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60:335\u201341. https:\/\/doi.org\/10.2967\/jnumed.118.213652.","journal-title":"J Nucl Med"},{"key":"5780_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","volume":"9","author":"L Goldfarb","year":"2019","unstructured":"Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9:8. https:\/\/doi.org\/10.1186\/s13550-019-0473-1.","journal-title":"EJNMMI Res"},{"issue":"6","key":"5780_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s00259-018-3988-1","volume":"45","author":"F Grizzi","year":"2018","unstructured":"Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 2018;45(6):1072\u20135. https:\/\/doi.org\/10.1007\/s00259-018-3988-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5780_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fonc.2020.01090","volume":"31","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Toschi L, Lopci E. Comparison of metabolic and morphological response criteria for early prediction of response and survival in NSCLC patients treated with anti-PD-1\/PD-L1. Front Oncol. 2020;31(10):1090. https:\/\/doi.org\/10.3389\/fonc.2020.01090.","journal-title":"Front Oncol"},{"issue":"5","key":"5780_CR32","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00432-020-03150-9","volume":"146","author":"A Castello","year":"2020","unstructured":"Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. J Cancer Res Clin Oncol. 2020;146(5):1235\u201343. https:\/\/doi.org\/10.1007\/s00432-020-03150-9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"5780_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2967\/jnumed.119.237768","volume":"61","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of 18F-FDG PET\/CT. J Nucl Med. 2020;61(6):821\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.237768.","journal-title":"J Nucl Med"},{"key":"5780_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44:67\u201377. https:\/\/doi.org\/10.1007\/s00259-017-3691-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","volume":"6","author":"CS Palmer","year":"2015","unstructured":"Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1. https:\/\/doi.org\/10.3389\/fimmu.2015.00001.","journal-title":"Front Immunol"},{"key":"5780_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04967-9","author":"N Ayati","year":"2020","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04967-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR37","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, et al. FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020;47:2776\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04815-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR38","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","volume":"46","author":"K Ito","year":"2019","unstructured":"Ito K, Schoder H, Teng R, Humm JL, Ni A, Wolchok JD, et al. Prognostic value of baseline metabolic tumor volume measured on (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging. 2019;46:930\u20139. https:\/\/doi.org\/10.1007\/s00259-018-4211-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. (18)F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging\u202f: the official publication of the International Cancer Imaging Society. 2020;20:36. https:\/\/doi.org\/10.1186\/s40644-020-00313-2.","journal-title":"Cancer Imaging : the official publication of the International Cancer Imaging Society"},{"key":"5780_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385\u201396. https:\/\/doi.org\/10.1093\/annonc\/mdz003.","journal-title":"Ann Oncol"},{"key":"5780_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2017.07.002","volume":"59","author":"P Queirolo","year":"2017","unstructured":"Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review. Cancer Treat Rev. 2017;59:71\u20138. https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.002.","journal-title":"Cancer Treat Rev"},{"key":"5780_CR42","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol. 2016;34:1510\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.64.0391.","journal-title":"J Clin Oncol."},{"key":"5780_CR43","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541\u20133. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870.","journal-title":"J Clin Oncol"},{"key":"5780_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1.","journal-title":"Lancet Oncol"},{"key":"5780_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/s0090-4295(98)00130-7","volume":"52","author":"BD Leibman","year":"1998","unstructured":"Leibman BD, Dillioglugil O, Abbas F, Tanli S, Kattan MW, Scardino PT. Impact of a clinical pathway for radical retropubic prostatectomy. Urology. 1998;52:94\u20139. https:\/\/doi.org\/10.1016\/s0090-4295(98)00130-7.","journal-title":"Urology"},{"key":"5780_CR46","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1002\/cam4.2797","volume":"9","author":"P Martin-Romano","year":"2020","unstructured":"Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, et al. Evidence of pseudoprogression in patients treated with PD1\/PDL1 antibodies across tumor types. Cancer Med. 2020;9:2643\u201352. https:\/\/doi.org\/10.1002\/cam4.2797.","journal-title":"Cancer Med"},{"key":"5780_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00262-020-02647-z","volume":"70","author":"A Bernard-Tessier","year":"2021","unstructured":"Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, et al. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother. 2021;70:221\u201332. https:\/\/doi.org\/10.1007\/s00262-020-02647-z.","journal-title":"Cancer Immunol Immunother"},{"key":"5780_CR48","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00259-019-04573-4","volume":"47","author":"O Humbert","year":"2020","unstructured":"Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, et al. (18)FDG PET\/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47:1158\u201367. https:\/\/doi.org\/10.1007\/s00259-019-04573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR49","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41571-019-0169-5","volume":"16","author":"M Gerwing","year":"2019","unstructured":"Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblatter M, et al. The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 2019;16:442\u201358. https:\/\/doi.org\/10.1038\/s41571-019-0169-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"5780_CR50","doi-asserted-by":"publisher","first-page":"566297","DOI":"10.3389\/fonc.2020.566297","volume":"10","author":"O Humbert","year":"2020","unstructured":"Humbert O, Chardin D. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:566297. https:\/\/doi.org\/10.3389\/fonc.2020.566297.","journal-title":"Front Oncol"},{"key":"5780_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.017.","journal-title":"Eur J Cancer"},{"key":"5780_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12885-020-6704-z","volume":"20","author":"T Tozuka","year":"2020","unstructured":"Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, et al. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1\/ligand 1 inhibitors. BMC Cancer. 2020;20:207. https:\/\/doi.org\/10.1186\/s12885-020-6704-z.","journal-title":"BMC Cancer"},{"key":"5780_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40425-019-0672-3","volume":"7","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, et al. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer. 2019;7:196. https:\/\/doi.org\/10.1186\/s40425-019-0672-3.","journal-title":"J Immunother Cancer"},{"key":"5780_CR54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jamaoncol.2020.1634","volume":"6","author":"B Kas","year":"2020","unstructured":"Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol. 2020;6:1039\u201346. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1634.","journal-title":"JAMA Oncol"},{"key":"5780_CR55","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543\u201352. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3676.","journal-title":"JAMA Oncol"},{"key":"5780_CR56","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23:1920\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1741.","journal-title":"Clin Cancer Res"},{"key":"5780_CR57","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3133.","journal-title":"Clin Cancer Res"},{"key":"5780_CR58","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdx178.","journal-title":"Ann Oncol"},{"key":"5780_CR59","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2967\/jnumed.120.242768","volume":"61","author":"RD Seban","year":"2020","unstructured":"Seban RD, Schwartz LH, Bonardel G, Dercle L. Diagnosis of hyperprogressive disease in patients treated with checkpoint inhibitors using (18)F-FDG PET\/CT. J Nucl Med. 2020;61:1404\u20135. https:\/\/doi.org\/10.2967\/jnumed.120.242768.","journal-title":"J Nucl Med"},{"key":"5780_CR60","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394. https:\/\/doi.org\/10.1200\/JCO.2014.56.2736.","journal-title":"J Clin Oncol"},{"key":"5780_CR61","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III Trials (checkMate 017 and checkMate 057). J Clin Oncol. 2017;35:3924\u201333. https:\/\/doi.org\/10.1200\/JCO.2017.74.3062.","journal-title":"J Clin Oncol"},{"key":"5780_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00114","volume":"3","author":"E Pons-Tostivint","year":"2019","unstructured":"Pons-Tostivint E, Latouche A, Vaflard P, Ricci F, Loirat D, Hescot S, et al. Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol. 2019;3:1\u201310. https:\/\/doi.org\/10.1200\/PO.18.00114.","journal-title":"JCO Precis Oncol."},{"key":"5780_CR63","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"AC Tan","year":"2018","unstructured":"Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018;29:2115\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdy330.","journal-title":"Ann Oncol"},{"key":"5780_CR64","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/1078-0432.CCR-20-0473","volume":"27","author":"S Champiat","year":"2021","unstructured":"Champiat S, Tselikas L, Farhane S, Raoult T, Texier M, Lanoy E, et al. Intratumoral immunotherapy: from trial design to clinical practice. Clin Cancer Res. 2021;27:665\u201379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0473.","journal-title":"Clin Cancer Res"},{"key":"5780_CR65","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","volume":"20","author":"E Deutsch","year":"2019","unstructured":"Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20:e452\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(19)30171-8.","journal-title":"Lancet Oncol"},{"key":"5780_CR66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2020.05.022","volume":"108","author":"G Ratnayake","year":"2020","unstructured":"Ratnayake G, Reinwald S, Shackleton M, Moore M, Voskoboynik M, Ruben J, et al. Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2020;108:150\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.05.022.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5780_CR67","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773\u201382. https:\/\/doi.org\/10.1016\/s0959-8049(99)00229-4.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"5780_CR68","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"5780_CR69","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/annonc\/mdx168","volume":"28","author":"J Le Lay","year":"2017","unstructured":"Le Lay J, Jarraya H, Lebellec L, Penel N. irRECIST and iRECIST: the devil is in the details. Ann Oncol. 2017;28:1676\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx168.","journal-title":"Ann Oncol"},{"key":"5780_CR70","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00259-020-05137-7","volume":"48","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, et al. Interim [(18)F]FDG PET\/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2021;48:1932\u201343. https:\/\/doi.org\/10.1007\/s00259-020-05137-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR71","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, et al. The role of interim (18)F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45:1289\u201396. https:\/\/doi.org\/10.1007\/s00259-018-3972-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR72","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","volume":"29","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC. 18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res. 2019;29:178\u201386. https:\/\/doi.org\/10.1097\/CMR.0000000000000541.","journal-title":"Melanoma Res"},{"key":"5780_CR73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/RLU.0000000000002921","volume":"45","author":"A Annovazzi","year":"2020","unstructured":"Annovazzi A, Vari S, Giannarelli D, Pasqualoni R, Sciuto R, Carpano S, et al. Comparison of 18F-FDG PET\/CT criteria for the prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors. Clin Nucl Med. 2020;45:187\u201394. https:\/\/doi.org\/10.1097\/RLU.0000000000002921.","journal-title":"Clin Nucl Med"},{"key":"5780_CR74","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2967\/jnumed.119.233056","volume":"61","author":"G Rossi","year":"2020","unstructured":"Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, et al. Comparison between (18)F-FDG PET-based and CT-based criteria in non-small cell lung cancer patients treated with Nivolumab. J Nucl Med. 2020;61:990\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.233056.","journal-title":"J Nucl Med"},{"key":"5780_CR75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","volume":"37","author":"A Lyall","year":"2012","unstructured":"Lyall A, Vargas HA, Carvajal RD, Ulaner G. Ipilimumab-induced colitis on FDG PET\/CT. Clin Nucl Med. 2012;37:629\u201330. https:\/\/doi.org\/10.1097\/RLU.0b013e318248549a.","journal-title":"Clin Nucl Med"},{"key":"5780_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04757-3","author":"RD Seban","year":"2020","unstructured":"Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04757-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04967-9","author":"N Ayati","year":"2020","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04967-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR78","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46:238\u201350. https:\/\/doi.org\/10.1007\/s00259-018-4171-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR79","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"RD Seban","year":"2019","unstructured":"Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298\u2013310. https:\/\/doi.org\/10.1007\/s00259-019-04411-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, et al. (18)F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin Lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. J Nucl Med. 2018;59:15\u201324. https:\/\/doi.org\/10.2967\/jnumed.117.193011.","journal-title":"J Nucl Med"},{"key":"5780_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05103-3","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, et al. Assessing immune organs on (18)F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-020-05103-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR82","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00262-018-2279-9","volume":"68","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Larribere L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Can benign lymphoid tissue changes in (18)F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother. 2019;68:297\u2013303. https:\/\/doi.org\/10.1007\/s00262-018-2279-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"5780_CR83","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"RD Seban","year":"2019","unstructured":"Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46(11):2298\u2013310. https:\/\/doi.org\/10.1007\/s00259-019-04411-7.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"5780_CR84","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020;47:1147\u201357. https:\/\/doi.org\/10.1007\/s00259-019-04615-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR85","doi-asserted-by":"publisher","unstructured":"Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.  Eur J Nucl Med Mol Imaging. 2020;47(10):2301\u201312. https:\/\/doi.org\/10.1007\/s00259-020-04757-3.","DOI":"10.1007\/s00259-020-04757-3"},{"key":"5780_CR86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid: official journal of the American Thyroid Association. 2020;30:177\u201384. https:\/\/doi.org\/10.1089\/thy.2019.0250.","journal-title":"Thyroid: official journal of the American Thyroid Association"},{"key":"5780_CR87","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4:374\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925.","journal-title":"JAMA Oncol"},{"key":"5780_CR88","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/rlu.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT. Clin Nucl Med. 2019;44:e272\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000002453.","journal-title":"Clin Nucl Med"},{"key":"5780_CR89","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24:111\u20135. https:\/\/doi.org\/10.1016\/j.acra.2016.08.005.","journal-title":"Acad Radiol"},{"key":"5780_CR90","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11:667\u201376. https:\/\/doi.org\/10.2217\/imt-2018-0146.","journal-title":"Immunotherapy"},{"key":"5780_CR91","doi-asserted-by":"publisher","first-page":"9523","DOI":"10.1200\/JCO.2016.34.15_suppl.9523","volume":"34","author":"A Wong","year":"2016","unstructured":"Wong A, Callahan J, Beresford J, Herschtal A, Fullerton S, Milne D. Spleen to liver ratio (SLR): novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. J Clin Oncol. 2016;34:9523\u201333.","journal-title":"J Clin Oncol"},{"key":"5780_CR92","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. https:\/\/doi.org\/10.1136\/bmj.k793.","journal-title":"BMJ"},{"key":"5780_CR93","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69:1751\u201363. https:\/\/doi.org\/10.1002\/acr.23177.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5780_CR94","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv623.","journal-title":"Ann Oncol"},{"key":"5780_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020;22:39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9.","journal-title":"Curr Oncol Rep"},{"key":"5780_CR96","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer. 2019;122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014.","journal-title":"Eur J Cancer"},{"key":"5780_CR97","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6.","journal-title":"Nat Rev Dis Primers"},{"key":"5780_CR98","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR99","first-page":"885","volume":"47","author":"D Delbeke","year":"2006","unstructured":"Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0. J Nucl Med. 2006;47:885\u201395.","journal-title":"J Nucl Med"},{"key":"5780_CR100","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1148\/radiol.2019191882","volume":"294","author":"PE Kinahan","year":"2020","unstructured":"Kinahan PE, Perlman ES, Sunderland JJ, Subramaniam R, Wollenweber SD, Turkington TG, et al. The QIBA profile for FDG PET\/CT as an imaging biomarker measuring response to cancer therapy. Radiology. 2020;294:647\u201357. https:\/\/doi.org\/10.1148\/radiol.2019191882.","journal-title":"Radiology"},{"key":"5780_CR101","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.115.158402","volume":"56","author":"MM Graham","year":"2015","unstructured":"Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, et al. Summary of the UPICT Protocol for 18F-FDG PET\/CT imaging in oncology clinical trials. J Nucl Med. 2015;56:955\u201361. https:\/\/doi.org\/10.2967\/jnumed.115.158402.","journal-title":"J Nucl Med"},{"key":"5780_CR102","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1148\/rg.2015150033","volume":"35","author":"KR Beckett","year":"2015","unstructured":"Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know. Radiographics. 2015;35:1738\u201350. https:\/\/doi.org\/10.1148\/rg.2015150033.","journal-title":"Radiographics"},{"key":"5780_CR103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","volume":"44","author":"N Aide","year":"2017","unstructured":"Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17\u201331. https:\/\/doi.org\/10.1007\/s00259-017-3740-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR104","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2018;52:5\u201315. https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","journal-title":"Nucl Med Mol Imaging"},{"key":"5780_CR105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00259-014-2903-7","volume":"42","author":"HJ Im","year":"2015","unstructured":"Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241\u201351. https:\/\/doi.org\/10.1007\/s00259-014-2903-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40658-017-0185-4","volume":"4","author":"C Lasnon","year":"2017","unstructured":"Lasnon C, Quak E, Le Roux PY, Robin P, Hofman MS, Bourhis D, et al. EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Phys. 2017;4:17. https:\/\/doi.org\/10.1186\/s40658-017-0185-4.","journal-title":"EJNMMI Phys"},{"key":"5780_CR107","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2967\/jnumed.115.171983","volume":"57","author":"E Quak","year":"2016","unstructured":"Quak E, Le Roux PY, Lasnon C, Robin P, Hofman MS, Bourhis D, et al. Does PET SUV harmonization affect PERCIST response classification? J Nucl Med. 2016;57:1699\u2013706. https:\/\/doi.org\/10.2967\/jnumed.115.171983.","journal-title":"J Nucl Med"},{"key":"5780_CR108","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-017-0279-y","volume":"7","author":"C Lasnon","year":"2017","unstructured":"Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7:30. https:\/\/doi.org\/10.1186\/s13550-017-0279-y.","journal-title":"EJNMMI Res"},{"key":"5780_CR109","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1148\/radiol.2018180078","volume":"289","author":"R Hamidizadeh","year":"2018","unstructured":"Hamidizadeh R, Eftekhari A, Wiley EA, Wilson D, Alden T, Benard F. Metformin discontinuation prior to FDG PET\/CT: a randomized controlled study to compare 24- and 48-hour bowel activity. Radiology. 2018;289:418\u201325. https:\/\/doi.org\/10.1148\/radiol.2018180078.","journal-title":"Radiology"},{"key":"5780_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cpet.2019.08.007","volume":"15","author":"RJ Hicks","year":"2020","unstructured":"Hicks RJ, Iravani A, Sandhu S. (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography for assessing tumor response to immunotherapy in solid tumors: melanoma and beyond. PET Clin. 2020;15:11\u201322. https:\/\/doi.org\/10.1016\/j.cpet.2019.08.007.","journal-title":"PET Clin"},{"key":"5780_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpet.2019.08.006","volume":"15","author":"K Prigent","year":"2020","unstructured":"Prigent K, Aide N. (18)F-Fludeoxyglucose PET\/Computed Tomography for assessing tumor response to immunotherapy and detecting immune-related side effects: a checklist for the PET reader. PET Clin. 2020;15:1\u201310. https:\/\/doi.org\/10.1016\/j.cpet.2019.08.006.","journal-title":"PET Clin"},{"key":"5780_CR112","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00259-021-05390-4","volume":"48","author":"N Aide","year":"2021","unstructured":"Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, et al. New PET technologies - embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48:2711\u201326. https:\/\/doi.org\/10.1007\/s00259-021-05390-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR113","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-021-00754-1","volume":"11","author":"O Jh","year":"2021","unstructured":"Jh O, Lim SJ, Wang H, Leal JP, Shu HG, Wahl RL, et al. Quantitation of cancer treatment response by 2-[(18)F]FDG PET\/CT: multi-center assessment of measurement variability using AUTO-PERCIST. EJNMMI Res. 2021;11:15. https:\/\/doi.org\/10.1186\/s13550-021-00754-1.","journal-title":"EJNMMI Res"},{"key":"5780_CR114","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","volume":"45","author":"R Slart","year":"2018","unstructured":"Slart R. FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250\u201369. https:\/\/doi.org\/10.1007\/s00259-018-3973-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5780_CR115","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2967\/jnumed.120.248823","volume":"61","author":"A Iravani","year":"2020","unstructured":"Iravani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacologic intervention, Part 2: the role of novel PET agents. J Nucl Med. 2020;61:1553\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.248823.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05780-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T01:05:55Z","timestamp":1653267955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5780"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05780-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"E.L. reports receiving grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and from the Italian Ministry of Health and faculty remuneration from ESMIT (European School of Multimodality Imaging and Therapy) and MI&T congressi. R. J.H. is on the Scientific Advisory Board of Telix Pharmaceuticals with any honoraria donated to his institution, he is a stock holder in this company, and he is also an honorary Trustee of the International Cancer Imaging Society and honorary Board Member of Neuroendocrine Cancer Australia. W.A.W. has been on the advisory boards and receives compensation from Blue Earth Diagnostics. N.P. declares honoraria from Actinium Pharmaceuticals, AstraZeneca\/MedImmune; Consulting or Advisory Role from Illumina, progenics; Speakers' Bureau from Actinium Pharmaceuticals; Research Funding from Bayer Health; Bristol-Myers Squibb; Clarity Pharmaceuticals; Imaginab; Janssen; Regeneron; Travel, Accommodations Expenses from Bayer. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}